7 results match your criteria: "Riga Stradins University Hospital[Affiliation]"
Is There a Difference in Outcomes Between Hemiarthroplasty and Total Hip Arthroplasty for Patients Who Have Displaced Femoral Neck Fractures?
J Arthroplasty
October 2024
Department of Surgery, McMaster University, Hamilton, Canada. Electronic address:
Prospective evaluation of the RT-PCR based urinary marker Bladder Epicheck® as a diagnostic tool in upper urinary tract tumor.
Minerva Urol Nephrol
April 2024
Department of Urology, Riga Stradins University Hospital, Riga, Latvia.
Background: Upper-tract-urothelial-carcinoma (UTUC) represents 5-10% of all urothelial-neoplasms with increasing incidence in the last decades. Current standard tools for diagnosis of UTUC include cytology, computed tomography (CT) urography and ureterorenoscopy (URS). The aim of this study was to evaluate the impact of Bladder Epicheck Test as diagnostic tool for UTUC diagnosis and recurrence.
View Article and Find Full Text PDFGiant Myxopapillary Ependymoma with Multi-Site Neural Axis Metastases: A Rare Case with Suboptimal Outcome.
Am J Case Rep
January 2024
Department of Pathology, Riga Stradiņš University Hospital, Riga, Latvia.
Article Synopsis
- A case study details a 44-year-old male with persistent lower back pain, where MRI identified a large tumor at L1-S4, leading to a biopsy that confirmed myxopapillary ependymoma, followed by partial tumor resection and radiation therapy due to observed metastases.
- Despite surgery, there remains a chance of tumor recurrence, highlighting the importance of preoperative imaging to check for metastases and the need for adjuvant treatments like radiation to reduce this risk.
Diagnostic value of Xpert Bladder Cancer Monitor in the follow-up of patients affected by non-muscle invasive bladder cancer: an update.
Ther Adv Urol
March 2021
Department of Urology, Bolzano General Hospital, Lorenz Böhler St 5, Bolzano, 39100, Italy.
Aims: Xpert Bladder Cancer Monitor is a urinary marker based on the evaluation of five target mRNAs overexpressed in patients with bladder cancer (BC). The aim of our study is to update our results regarding the diagnostic accuracy of the Xpert Bladder Cancer Monitor test in the follow-up of patients with non-muscle invasive bladder cancer (NMIBC).
Methods: We conducted a prospective study on 1015 samples of 416 patients (mean age 72.
Comparison of 2 new real-time polymerase chain reaction-based urinary markers in the follow-up of patients with non-muscle-invasive bladder cancer.
Cancer Cytopathol
May 2020
Department of Urology, Central Hospital of Bolzano, Bolzano, Italy.
Background: The objective of the current study was to compare the diagnostic accuracy of 2 new real-time polymerase chain reaction-based urinary markers with each other and with urinary cytology, cystoscopy, and/or histology in patients being followed for non-muscle-invasive bladder cancer.
Methods: A total of 487 patients were enrolled in the study. Patients were evaluated using voided urine cytology, the Xpert Bladder Cancer Monitor, the Bladder EpiCheck test, and white light cystoscopy.
Diagnostic predictive value of Xpert Bladder Cancer Monitor in the follow-up of patients affected by non-muscle invasive bladder cancer.
J Clin Pathol
February 2019
Department of Urology, Central Hospital of Bolzano, Bolzano, Italy.
Aims: Cystoscopy and urine cytology represent the gold standard for monitoring superficial bladder cancer (BC). Xpert BC Monitor is a new urinary marker based on the evaluation of five target mRNAs overexpressed in patients with bladder cancer. The aim of our study was to evaluate the diagnostic accuracy of Xpert BC Monitor in follow-up of patients with non-muscle invasive bladder cancer (NMIBC).
View Article and Find Full Text PDFPlatinum-Based Chemotherapy Secures Effective Local Control for Very Advanced Hereditary Triple-Negative Breast Cancer with Life-Threatening Bleeding.
Cureus
July 2017
Chief of Surgical Department, Riga Stradins University Hospital, Riga Stradins University, Latvia.
Here we report the case of a noncompliant 50-year-old female patient with high-grade, triple-negative breast cancer (TNBC) and strong family cancer history. She only agreed to start treatment after being admitted to the hospital with advanced stage disease and severe anaemia resulting from bulky, ulcerated, and actively bleeding tumor. Therapy was promptly started with platinum-based chemotherapy, resulting in extremely rapid clinical remission and complete control of local symptoms.
View Article and Find Full Text PDF